Skip to main content
OpenTrials
Completed

NCT Number: NCT02168738

Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules.

The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Subject

Age range

60 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Centre de Recherche en Nutrition Humaine Rhône-Alpes, 165 chemin du Grand Revoyet,

Pierre-Bénite, 69310, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male
  • Aged of 60 to 70 years
  • Body Mass Index of 20 to 30 kg/m2
  • Glycaemic and lipid parameters normal

Exclusion criteria

  • Smokers more than ten cigarettes/day
  • Medical history of personal or family dyslipidemia
  • Medication that could interfere with lipid metabolism

Treatment and study plan

13-C labeled AceDoPC-DHA

Drug

Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.

The dose contains 50 mg 13C-DHA. The wash-out period is four months

13-C labeled TG-DHA

Drug

Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.

The dose contains 50 mg 13C-DHA. The wash-out period is four months

13-C labeled PC-DHA

Drug

Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.

The dose contains 50 mg 13C-DHA. The wash-out period is four months

Primary outcomes

  1. Concentration of 13C-DHA in red blood cells

    Time frame: At Day 1

    6 hours after product ingestion

Secondary outcomes

  1. Concentration of 13C-DHA in plasma lipids

    Time frame: At Day 1

    6 hours after product ingestion

  2. Concentration of 13C-DHA in platelets

    Time frame: At Day 1

    6 hours after product ingestion

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human

Acronym: AceDoPC

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jun 20, 2014
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.